loading page

Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
  • Abdullah Mohammad Arshad,
  • mohamed yassin
Abdullah Mohammad Arshad
Hamad Medical Corporation
Author Profile
mohamed yassin
HMC NCCCR
Author Profile

Abstract

Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.

Peer review status:UNDER REVIEW

17 Dec 2020Submitted to Clinical Case Reports
21 Dec 2020Assigned to Editor
21 Dec 2020Submission Checks Completed
05 Sep 2021Reviewer(s) Assigned